October 2015 Gynecologic Trials

Principle Investigator:
Sharad Ghamande, MD

“GOG-0229O; A Randomized Phase II Study with a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer” Sponsor: National Cancer Institute (NCI)

“GOG-0264;  A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary” Sponsor: Gynecologic Oncology Group

“GOG-0275; A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia” Sponsor: Gynecologic Oncology Group

“A011106; ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study” Sponsor: Alliance for Clinical Trials in Oncology

“PM1183-C-004-14; Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)” Sponsor: Pharma Mar USA, Inc.